BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 16, 2008
 |  BioCentury  |  Strategy

DPP-4 traffic jam

DPP-4 traffic jam

By Michael Flanagan Senior Writer

Unlike the next wave of GLP-1 mimetics, which are expected to offer successively less frequent dosing and easier compliance for Type II diabetics, data on the new contingent of DPP-4 inhibitors at last week's American Diabetes Association meeting didn't show any obvious advantages over Januvia sitagliptin from Merck & Co. Inc.

Given the apparent similarities in potency, dosing and side effect profiles, the question remains whether doctors will use a newer DPP-4 instead of one with a proven track record. The first company to test the waters could be Takeda Pharmaceutical Co. Ltd., which submitted an NDA late last year for its alogliptin.

Dipeptidyl peptidase-4 enzymes break down glucagon-like peptide-1, an incretin hormone that reduces the amount of glucose in circulation by stimulating pancreatic beta cells to produce insulin and alpha cells to stop producing glucagon. In October 2006, Januvia became the first small molecule DPP-4 inhibitor approved to treat Type II diabetes in the U.S. (see BioCentury, Oct. 23, 2006).

James Lane, associate professor at the University of Nebraska Medical Center, noted Januvia is a pill that only needs to be taken once a day, and has a remarkably clean side effect profile that does not carry the same risk of hypoglycemia...

Read the full 1065 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >